Skip to main content

Rosetta Posts Increased Revenues, Losses for 2014

NEW YORK (GenomeWeb) – Rosetta Genomics reported today after the close of the market a 228 percent jump in 2014 revenues, derived primarily from the sale of its microRNA-based diagnostics.

The company's revenues from continuing operations jumped to $1.3 million last year from $405,000 the year before.

Rosetta's net loss after discontinued operations was $14.5 million, or $1.29 a share on 11.2 million shares outstanding, versus $12.9 million, or $1.34 a share, on 9.6 million shares outstanding, in 2013.

On a non-GAAP basis, Rosetta's net loss for 2014 was $13.6 million, or $1.21 a share, compared with $12 million, or $1.25 per share, a year earlier.

Rosetta's research and development costs edged up to $1.9 million in 2014 from $1.7 million the year before. Its SG&A costs, meantime, rose to $12.3 million from $11.3 million.

As of December 31, 2014, Rosetta had cash and cash equivalents totaling $7.9 million, versus $16.8 million at the end of 2013.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.